Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA vs D/IA Induction in Elderly AML Patients
NCT07132684Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax, azacitidine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2025; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07132684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132684.